3 enrolling by invitation. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Enrolling by invitation 3 |
Follow Gallbladder Diseases: new trials by email Literature Review of Gallbladder Diseases trials Research Report on Gallbladder Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cancer Treatment :Gemcitabine plus Nab-Paclitaxel (AG regimen) in combination with Iparomlimab and Tuvorili - Gallbladder Cancer Unresectable | Phase 2 | Enrolling by invitation | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 44 | 2025-05-01 | 2025-12-30 |
| Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma Camrelizumab, anlotinib, nab-paclitaxel, S-1, Camrelizumab, nab-paclitaxel, S-1 - Gallbladder Cancer and Extrahepatic Cholangiocarcinoma | Phase 2 | Enrolling by invitation | The First Affiliated Hospital of Zhengzhou University | 50 | 2024-11-08 | 2025-03-30 |
| Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT) Gemcitabine nab-PaclitaxelLenvatinibTislelizumab - Gallbladder Cancer, Cholangiocarcinoma | Phase 2 | Enrolling by invitation | Wei Gong | 44 | 2024-06-01 | 2025-05-08 |
Gallbladder Neoplasms (3) · Cholangiocarcinoma (2)
Biliary Tract Diseases (3) · Biliary Tract Neoplasms (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Neoplasms (3) · Neoplasms by Site (3) · Adenocarcinoma (2) · Carcinoma (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2)
130-nm albumin-bound paclitaxel (2) · S 1 (combination) (1) · anlotinib (1) · camrelizumab (1)
The First Affiliated Hospital of Zhengzhou University (1) · Wei Gong (1) · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (1)
China (3)
Wei Gong (1)